David Piccioni

7.0k total citations · 1 hit paper
94 papers, 2.7k citations indexed

About

David Piccioni is a scholar working on Genetics, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, David Piccioni has authored 94 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Genetics, 34 papers in Pulmonary and Respiratory Medicine and 31 papers in Cancer Research. Recurrent topics in David Piccioni's work include Glioma Diagnosis and Treatment (51 papers), Cancer Genomics and Diagnostics (24 papers) and Brain Metastases and Treatment (20 papers). David Piccioni is often cited by papers focused on Glioma Diagnosis and Treatment (51 papers), Cancer Genomics and Diagnostics (24 papers) and Brain Metastases and Treatment (20 papers). David Piccioni collaborates with scholars based in United States, Netherlands and Japan. David Piccioni's co-authors include Razelle Kurzrock, Santosh Kesari, Paul T. Fanta, Maria Schwaederlé, Shumei Kato, Barbara A. Parker, Scott M. Lippman, Richard B. Schwab, Jason K. Sicklick and Vincent A. Miller and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

David Piccioni

84 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study

2019 429 citations Jason K. Sicklick, Shumei Kato et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Piccioni United States	25	1.1k	998	861	821	733	94	2.7k
In Ah Kim South Korea	29	874 0.8×	987 1.0×	757 0.9×	1.1k 1.3×	617 0.8×	162	3.0k
Carmen Balañá Spain	25	644 0.6×	774 0.8×	848 1.0×	839 1.0×	1.2k 1.7×	119	2.7k
Benoît Lhermitte France	18	647 0.6×	710 0.7×	702 0.8×	821 1.0×	1.1k 1.5×	77	2.5k
Magalie Hilton Switzerland	12	665 0.6×	775 0.8×	1.0k 1.2×	692 0.8×	1.5k 2.1×	24	2.6k
Jennifer S. Yu United States	24	569 0.5×	869 0.9×	826 1.0×	1.2k 1.5×	823 1.1×	91	2.6k
Jeannette M. Dowell United States	18	785 0.7×	1.1k 1.1×	692 0.8×	1.3k 1.6×	1.4k 1.9×	19	3.2k
Radek Lakomý Czechia	22	1.0k 0.9×	1.3k 1.3×	806 0.9×	1.2k 1.5×	296 0.4×	87	2.8k
Pierre-Yves Dietrich Switzerland	13	569 0.5×	624 0.6×	536 0.6×	942 1.1×	1.5k 2.0×	14	2.5k
Fonnet E. Bleeker Netherlands	19	1.1k 1.0×	453 0.5×	435 0.5×	1.4k 1.7×	1.3k 1.8×	43	2.7k
S. Andrew United States	34	885 0.8×	741 0.7×	583 0.7×	2.2k 2.7×	1.6k 2.2×	84	4.2k

Countries citing papers authored by David Piccioni

Since Specialization

Citations

This map shows the geographic impact of David Piccioni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Piccioni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Piccioni more than expected).

Fields of papers citing papers by David Piccioni

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Piccioni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Piccioni. The network helps show where David Piccioni may publish in the future.

Co-authorship network of co-authors of David Piccioni

This figure shows the co-authorship network connecting the top 25 collaborators of David Piccioni. A scholar is included among the top collaborators of David Piccioni based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Piccioni. David Piccioni is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sicklick, Jason K., Daisuke Nishizaki, Hirotaka Miyashita, et al.. (2026). Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy (I-PREDICT) N-of-1 Precision Oncology Study: Molecular Profiling to Match Individually Dosed, Personalized Drug Combinations. Journal of Clinical Oncology. 44(7). 540–552.

Bota, Daniela A., David Piccioni, Christopher Duma, et al.. (2025). Phase 2 trial of personal dendritic cell vaccines in newly diagnosed glioblastoma: 3-year follow-up and correlations with survival. Human Vaccines & Immunotherapeutics. 21(1). 2556591–2556591.

Kumthekar, Priya, Michael Youssef, Jonathan T. Yang, et al.. (2024). BMRK-13 CSF TUMOR CELL (CSF-TC) DETECTION, QUANTIFICATION AND BIOMARKER ASSESSMENT HELPS IN CLINICAL MANAGEMENT OF BREAST CANCER AND NON-SMALL CELL LUNG CANCER PATIENTS HAVING LEPTOMENINGEAL DISEASE (FORESEE STUDY, NCT05414123). Neuro-Oncology Advances. 6(Supplement_1). i11–i11.

Dmello, Crismita, Andrew Brenner, David Piccioni, et al.. (2024). Phase II trial of blood–brain barrier permeable peptide-paclitaxel conjugate ANG1005 in patients with recurrent high-grade glioma. Neuro-Oncology Advances. 6(1). vdae186–vdae186. 6 indexed citations

Dennis, Michael J., Dean C. Pavlick, Alec Kacew, et al.. (2024). Low PD-L1 expression, MAP2K2 alterations, and enriched HPV gene signatures characterize brain metastases in head and neck squamous cell carcinoma. Journal of Translational Medicine. 22(1). 960–960. 2 indexed citations

Kumthekar, Priya, et al.. (2024). The HER2 flip-HER2 amplification of tumor cells in the cerebrospinal fluid of breast cancer patients with leptomeningeal disease: implications for treating the LM tumor with anti-HER2 therapy. Frontiers in Oncology. 14. 1402651–1402651. 4 indexed citations

Piccioni, David, et al.. (2023). Radiographic evolution of myelitis in a case of glial fibrillary acidic protein (GFAP) astrocytopathy. BMJ Case Reports. 16(3). e248921–e248921. 5 indexed citations

Fu, Siqing, David Piccioni, Hongtao Liu, et al.. (2021). A phase I study of the WT2725 dosing emulsion in patients with advanced malignancies. Scientific Reports. 11(1). 22355–22355. 13 indexed citations

Kumthekar, Priya, Shou‐Ching Tang, Andrew Brenner, et al.. (2020). ANG1005, a Brain-Penetrating Peptide–Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases. Clinical Cancer Research. 26(12). 2789–2799. 178 indexed citations

10.

Bahrami, Naeim, David Piccioni, Roshan Karunamuni, et al.. (2018). Edge Contrast of the FLAIR Hyperintense Region Predicts Survival in Patients with High-Grade Gliomas following Treatment with Bevacizumab. American Journal of Neuroradiology. 39(6). 1017–1024. 17 indexed citations

11.

Chang, Victoria A., Daniel R. Simpson, Gregory A. Daniels, & David Piccioni. (2018). Infliximab for treatment-refractory transverse myelitis following immune therapy and radiation. Journal for ImmunoTherapy of Cancer. 6(1). 153–153. 30 indexed citations

12.

Millis, Sherri Z., David Piccioni, Paul T. Fanta, et al.. (2017). Next-Generation Sequencing in the Clinical Setting Clarifies Patient Characteristics and Potential Actionability. Cancer Research. 77(22). 6313–6320. 22 indexed citations

13.

Schwaederlé, Maria, Ranajoy Chattopadhyay, Shumei Kato, et al.. (2017). Genomic Alterations in Circulating Tumor DNA from Diverse Cancer Patients Identified by Next-Generation Sequencing. Cancer Research. 77(19). 5419–5427. 89 indexed citations

14.

Krishnan, Anitha Priya, Roshan Karunamuni, Kelly M. Leyden, et al.. (2017). Restriction Spectrum Imaging Improves Risk Stratification in Patients with Glioblastoma. American Journal of Neuroradiology. 38(5). 882–889. 13 indexed citations

15.

Saria, Marlon Garzo, Lorraine S. Evangelista, Adeline Nyamathi, et al.. (2017). Anxiety and Depression Associated With Burden in Caregivers of Patients With Brain Metastases. Oncology nursing forum. 44(3). 306–315. 20 indexed citations

16.

Schwaederlé, Maria, Hatim Husain, Paul T. Fanta, et al.. (2016). Use of Liquid Biopsies in Clinical Oncology: Pilot Experience in 168 Patients. Clinical Cancer Research. 22(22). 5497–5505. 102 indexed citations

17.

Schwaederlé, Maria, Barbara A. Parker, Richard B. Schwab, et al.. (2016). Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience. Molecular Cancer Therapeutics. 15(4). 743–752. 125 indexed citations

18.

Tang, Shou‐Ching, Priya Kumthekar, Andrew Brenner, et al.. (2016). ANG1005, a novel peptide-paclitaxel conjugate crosses the BBB and shows activity in patients with recurrent CNS metastasis from breast cancer, results from a phase II clinical study. Annals of Oncology. 27. vi103–vi103. 16 indexed citations

19.

Schwaederlé, Maria, Gregory A. Daniels, David Piccioni, et al.. (2015). On the Road to Precision Cancer Medicine: Analysis of Genomic Biomarker Actionability in 439 Patients. Molecular Cancer Therapeutics. 14(6). 1488–1494. 71 indexed citations

20.

Breitweg, J., DS Bailey, S. Campbell-Robson, et al.. (1998). Measurement of the diffractive structure function F2D(4) at HERA. Homo Politicus (Academy of Humanities and Economics in Lodz). 81–96. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact